compared the synergism of HPV peptides and iNKT cell agonist α-GalCer vaccination with various checkpoint inhibitor or agonist antibodies and demonstrated an exceptional growth control of TC-1 tumors with anti-4-1BB antibody combination but not with anti-PD-1.27 In order to test if anti-4-1BB antibody treatment would also synergize with nanoparticle vaccines delivered via the iv route, we utilized the TC-1 mouse adenocarcinoma cell line which expresses the HPV E6 and E7 oncogenes as a relevant antigen for human cervical cancers. Here, TNFRSF9 is linked to cervical carcinoma.